



# Introduction to MenQuadfi Label Change for Infants

**Sarah Schillie, MD, MPH, MBA**

Advisory Committee on Immunization Practices

April 16, 2025

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U. S. Centers for Disease Control and Prevention.

# MenACWY Vaccines Available for Use in the United States\*

| Manufacturer              | Trade Name          | Abbreviation         | Licensed Age Group           | ACIP Recommended Age Group* |
|---------------------------|---------------------|----------------------|------------------------------|-----------------------------|
| <del>Sanofi Pasteur</del> | <del>Menactra</del> | <del>MenACWY-D</del> | <del>9 months–55 years</del> | <del>≥9 months</del>        |
| Sanofi Pasteur            | MenQuadfi           | MenACWY-TT           | ≥2 years                     | ≥2 years                    |
| GlaxoSmithKline           | Menveo              | MenACWY-CRM          | 2 months–55 years            | ≥2 months**                 |

\*Same product preferred, but not required, for all doses in a series

\*\*Includes off-label recommendations for persons 56 years and older

# MenACWY Vaccine Recommendations\*

- Routinely recommended for persons at age 11–12 years and 16 years
- Recommended for persons aged  $\geq 2$  months with risk factors:
  - Complement component deficiencies or complement inhibitor use
  - Anatomic or functional asplenia
  - HIV infection
  - Microbiologists routinely exposed to *N. meningitidis* isolates
  - Persons at increased risk during an outbreak
  - Persons who live in or travel to countries in which meningococcal disease is hyperendemic or epidemic

\*Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020;69(No. RR-9):1–41. DOI: <http://dx.doi.org/10.15585/mmwr.rr6909a1>.

# MenACWY Vaccine Recommendations for Persons with Risk Factors\*

- <2 Years:
  - Age 2 months: 4-dose series (2, 4, 6, 12 mos)
  - Age 3–6 months: 3- or 4-dose series (dose 2 [and dose 3 if applicable]  $\geq 8$  wks after previous dose until a dose is received at age  $\geq 7$  mos, followed by an additional dose  $\geq 12$  wks later and at age  $> 12$  mos)
  - Age 7–23 months: 2-dose series (dose 2  $\geq 12$  wks after dose 1 and at age  $> 12$  mos)
- $\geq 2$  Years: 2-dose primary series, with doses separated by 8 wks\*\*
- Booster dose:
  - Age  $< 7$  years: 3 yrs after primary series and every 5 yrs thereafter
  - Age  $\geq 7$  years: 5 yrs after primary series and every 5 yrs thereafter

\*Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020;69(No. RR-9):1–41. DOI: <http://dx.doi.org/10.15585/mmwr.rr6909a1>.

\*\*Medical risk factors

# MenQuadfi Proposed Licensure in Infants

- With discontinuation of Menactra, Menveo is the only MenACWY vaccine available in the United States for persons under 2 years of age
- Sanofi Pasteur seeking infant indication for MenQuadfi for the following ages at initiation (anticipated May 2025):
  - 6 weeks–5 months: 2, 4, 6, 12–18 months (first dose may be administered as early as 6 weeks)
  - 6–23 months: 2-dose series with 2<sup>nd</sup> dose administered in second year of life and  $\geq 3$  months after 1<sup>st</sup> dose
  - $\geq 2$  years: 1 dose

# Acknowledgements

- Lucy McNamara
- Avnika Amin
- Amy Rubis
- Susan Hariri
- Noele Nelson
- LeAnne Fox
- Alison Albert